BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CLN-049 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CLN-049\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07722767-2986@assetmemo.bio
DTSTAMP:20261121T005838Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:CLN-049: Phase 1 readout est. (NCT07722767)
DESCRIPTION:CLN-049\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Phase 1b 
 Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Pat
 ients\nEstimated primary completion: 30 September 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/cln-049#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07722767
URL:https://assetmemo.bio/drug/cln-049#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05143996-2986@assetmemo.bio
DTSTAMP:20261121T005838Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:CLN-049: Phase 1/2 readout est. (NCT05143996)
DESCRIPTION:CLN-049\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: CLN-049 i
 n Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelod
 ysplastic Syndrome (MDS)\nEstimated primary completion: 30 December 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/cln-049#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05143996
URL:https://assetmemo.bio/drug/cln-049#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
